Adult sickle cell disease patients have historically faced limited curative options, with bone marrow transplantation traditionally reserved for children due to increased toxicity risks in older recipients. This reality has left many adults managing a progressive disease that can lead to organ damage, stroke, and shortened lifespan, creating an urgent need for safer transplant protocols that extend curative therapy beyond childhood.
A multi-center trial of 25 patients with a median age of 26.7 years tested a modified conditioning regimen combining thymoglobulin, thiotepa, cyclophosphamide, fludarabine, and low-dose radiation (200 cGy), followed by post-transplant cyclophosphamide prophylaxis. The protocol achieved remarkable results: 96% event-free survival at five years, 100% two-year overall survival, and complete donor cell engraftment in all patients. Notably, 81% of evaluable participants discontinued immunosuppression within one year, and no graft failures occurred—even among three patients who had previously experienced transplant failures.
This represents a potential paradigm shift in sickle cell treatment, demonstrating that carefully designed reduced-intensity conditioning can deliver curative outcomes in adults without the prohibitive toxicity that has historically limited transplantation to pediatric populations. The incorporation of post-transplant cyclophosphamide appears particularly crucial, as this approach has revolutionized transplant medicine by reducing graft-versus-host disease while maintaining anti-tumor effects. However, the study's modest size and single-arm design warrant cautious interpretation. Larger randomized trials comparing this protocol to standard care will be essential to establish its broader applicability and confirm these promising early results across diverse adult sickle cell populations.